Symbols / ONC Stock $293.27 -3.73% BeOne Medicines AG

Healthcare • Biotechnology • Switzerland • NMS
ONC (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. John V. Oyler
Exch · Country NMS · Switzerland
Market Cap 30.43B
Enterprise Value 420.21B
Income 513.02M
Sales 5.74B
FCF (ttm) 917.30M
Book/sh 42.84
Cash/sh 3.31
Employees 12,000
Insider 10d —
IPO Feb 03, 2016
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 66.20
Forward P/E 32.45
PEG —
P/S 5.30
P/B 6.85
P/C —
EV/EBITDA 509.11
EV/Sales 73.22
Quick Ratio 3.17
Current Ratio 3.64
Debt/Eq 24.14
LT Debt/Eq —
EPS (ttm) 4.43
EPS next Y 9.04
EPS Growth 169.71%
Revenue Growth 35.50%
EPS Gr Q/Q 178.02%
Rev Gr Q/Q —
Earnings (next) 2026-08-05
Earnings (prior) 2026-05-06
ROA 5.96%
ROE 12.42%
ROIC —
Gross Margin 88.31%
Oper. Margin 16.51%
Profit Margin 8.94%
Shs Outstand 94.90M
Shs Float 1.01B
Insider Own 17.29%
Instit Own 33.46%
Short Float 1.56%
Short Ratio 5.45
Short Interest 1.11M
52W High 385.22
vs 52W High -23.87%
52W Low 228.93
vs 52W Low 28.11%
Beta 0.50
Impl. Vol. 49.89%
Rel Volume 1.12
Avg Volume 241.85K
Volume 269.68K
Target (mean) $411.38
Tgt Median $409.00
Tgt Low $333.00
Tgt High $501.30
# Analysts 27
Recom Strong_buy
Prev Close $304.62
Price $293.27
Change -3.73%
About

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$411.38
Mean price target
2. Current target
$293.27
Latest analyst target
3. DCF / Fair value
$173.99
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$293.27
Low
$333.00
High
$501.30
Mean
$411.38

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-15 main Leerink Partners Outperform → Outperform $367
2026-05-07 main RBC Capital Outperform → Outperform $425
2026-05-07 main Barclays Overweight → Overweight $409
2026-05-07 main Guggenheim Buy → Buy $420
2026-05-07 reit Truist Securities Buy → Buy $413
2026-05-04 init Wells Fargo — → Overweight $400
2026-03-27 init Wolfe Research — → Outperform $340
2026-03-16 down Jefferies Buy → Hold $290
2026-02-27 main RBC Capital Outperform → Outperform $425
2026-02-27 main Truist Securities Buy → Buy $412
2026-02-27 main Guggenheim Buy → Buy $410
2026-02-27 main Barclays Overweight → Overweight $405
2026-02-04 main Barclays Overweight → Overweight $394
2025-11-24 init Truist Securities — → Buy $400
2025-11-18 main RBC Capital Outperform → Outperform $408
2025-11-10 main Citigroup Buy → Buy $405
2025-11-07 main RBC Capital Outperform → Outperform $395
2025-11-07 main Citizens Market Outperform → Market Outperform $396
2025-10-20 main Morgan Stanley Overweight → Overweight $383
2025-10-08 main JP Morgan Overweight → Overweight $385
News
RSS: Latest ONC news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-08 LEE CHAN HENRY General Counsel — 332 $311.59 $103,448
2026-04-08 LEE CHAN HENRY General Counsel — 332 $159.03 $63,598
2026-03-11 LEE CHAN HENRY General Counsel — 341 $300.00 $102,300
2026-03-11 LEE CHAN HENRY General Counsel — 341 $159.03 $65,348
2026-02-04 LEE CHAN HENRY General Counsel — 1,660 $348.79 $580,197
2026-02-04 LEE CHAN HENRY General Counsel — 1,660 $159.03 $317,721
2026-01-07 LEE CHAN HENRY General Counsel — 664 $331.76 $220,289
2026-01-07 LEE CHAN HENRY General Counsel — 664 $159.03 $127,196
2025-12-16 OYLER JOHN VICTOR Chief Executive Officer — 100,000 $300.80 $30,659,419
2025-12-11 LEE CHAN HENRY General Counsel — 664 $318.28 $213,569
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
5,343.03
+40.23%
3,810.24
+54.96%
2,458.78
+73.65%
1,415.92
Operating Revenue
6,789.29
+41.07%
4,812.84
+61.30%
2,983.72
+87.62%
1,590.26
Cost Of Revenue
668.54
+12.53%
594.09
+56.37%
379.92
+32.62%
286.48
Reconciled Cost Of Revenue
668.54
+12.53%
594.09
+56.37%
379.92
+32.62%
286.48
Gross Profit
4,674.49
+45.34%
3,216.15
+54.71%
2,078.86
+84.06%
1,129.45
Operating Expense
4,227.36
+11.71%
3,784.35
+15.15%
3,286.59
+12.59%
2,919.11
Research And Development
2,145.87
+9.86%
1,953.30
+9.82%
1,778.59
+8.42%
1,640.51
Selling General And Administration
2,081.49
+13.68%
1,831.06
+21.42%
1,508.00
+17.94%
1,278.60
Total Expenses
4,895.90
+11.82%
4,378.44
+19.42%
3,666.51
+14.38%
3,205.59
Operating Income
447.14
+178.69%
-568.20
+52.95%
-1,207.74
+32.52%
-1,789.66
Total Operating Income As Reported
447.14
+178.69%
-568.20
+52.95%
-1,207.74
+32.52%
-1,789.66
EBITDA
616.77
+281.71%
-339.43
+53.74%
-733.80
+57.42%
-1,723.39
Normalized EBITDA
616.77
+281.71%
-339.43
+53.74%
-733.80
+57.42%
-1,723.39
Reconciled Depreciation
141.69
-17.51%
171.76
+95.91%
87.67
+32.28%
66.28
EBIT
475.09
+192.94%
-511.20
+37.77%
-821.47
+54.10%
-1,789.66
Net Income
286.93
+144.50%
-644.79
+26.87%
-881.71
+56.00%
-2,003.82
Pretax Income
416.85
+178.21%
-533.00
+35.46%
-825.84
+57.89%
-1,961.04
Net Non Operating Interest Income Expense
12.27
-74.35%
47.84
-35.36%
74.01
+41.02%
52.48
Interest Expense Non Operating
58.23
+167.07%
21.80
+399.66%
4.36
—
Net Interest Income
12.27
-74.35%
47.84
-35.36%
74.01
+41.02%
52.48
Interest Expense
58.23
+167.07%
21.80
+399.66%
4.36
—
Interest Income Non Operating
70.50
+1.24%
69.64
-11.14%
78.37
+49.34%
52.48
Interest Income
70.50
+1.24%
69.64
-11.14%
78.37
+49.34%
52.48
Other Income Expense
-42.55
-236.71%
-12.64
-104.10%
307.89
+237.54%
-223.85
Other Non Operating Income Expenses
-42.55
-236.71%
-12.64
-104.10%
307.89
+237.54%
-223.85
Tax Provision
129.92
+16.22%
111.78
+100.07%
55.87
+30.61%
42.78
Tax Rate For Calcs
0.00
+48.57%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
286.93
+144.50%
-644.79
+26.87%
-881.71
+56.00%
-2,003.82
Net Income From Continuing Operation Net Minority Interest
286.93
+144.50%
-644.79
+26.87%
-881.71
+56.00%
-2,003.82
Net Income From Continuing And Discontinued Operation
286.93
+144.50%
-644.79
+26.87%
-881.71
+56.00%
-2,003.82
Net Income Continuous Operations
286.93
+144.50%
-644.79
+26.87%
-881.71
+56.00%
-2,003.82
Minority Interests
—
—
—
0.00
Normalized Income
286.93
+144.50%
-644.79
+26.87%
-881.71
+56.00%
-2,003.82
Net Income Common Stockholders
286.93
+144.50%
-644.79
+26.87%
-881.71
+56.00%
-2,003.82
Diluted EPS
2.47
+140.33%
-6.12
+27.53%
-8.45
+56.38%
-19.37
Basic EPS
2.60
+142.55%
-6.11
+27.69%
-8.45
+56.38%
-19.37
Basic Average Shares
109.06
+3.58%
105.29
+0.86%
104.39
+1.22%
103.13
Diluted Average Shares
113.45
+7.75%
105.29
+0.86%
104.39
+1.22%
103.13
Diluted NI Availto Com Stockholders
286.93
+144.50%
-644.79
+26.87%
-881.71
+56.00%
-2,003.82
Amortization
—
—
3.50
+366.05%
0.75
Amortization Of Intangibles Income Statement
—
—
3.50
+366.05%
0.75
Depreciation Amortization Depletion Income Statement
—
—
3.50
+366.05%
0.75
Depreciation And Amortization In Income Statement
—
—
3.50
+366.05%
0.75
Total Other Finance Cost
—
—
-74.01
-41.02%
-52.48
Line Item Trend 2025-12-31
Total Assets
8,188.57
Current Assets
6,233.59
Cash Cash Equivalents And Short Term Investments
4,547.53
Cash And Cash Equivalents
4,547.53
Other Short Term Investments
—
Receivables
886.86
Accounts Receivable
865.08
Gross Accounts Receivable
—
Allowance For Doubtful Accounts Receivable
—
Other Receivables
21.78
Accrued Interest Receivable
—
Inventory
608.23
Raw Materials
236.19
Work In Process
122.68
Finished Goods
249.36
Prepaid Assets
130.73
Restricted Cash
41.28
Other Current Assets
18.96
Total Non Current Assets
1,954.98
Net PPE
1,715.95
Gross PPE
2,244.64
Accumulated Depreciation
-528.70
Properties
0.00
Land And Improvements
71.43
Buildings And Improvements
1,187.84
Machinery Furniture Equipment
124.14
Construction In Progress
132.12
Other Properties
652.55
Leases
76.57
Goodwill And Other Intangible Assets
141.58
Goodwill
—
Other Intangible Assets
141.58
Investments And Advances
61.68
Non Current Deferred Assets
—
Non Current Deferred Taxes Assets
—
Non Current Prepaid Assets
4.47
Other Non Current Assets
31.30
Total Liabilities Net Minority Interest
3,827.38
Current Liabilities
1,828.83
Payables And Accrued Expenses
1,324.72
Payables
614.58
Accounts Payable
479.04
Other Payable
33.56
Current Accrued Expenses
710.14
Employee Benefits
18.17
Pensionand Other Post Retirement Benefit Plans Current
305.06
Total Tax Payable
101.98
Current Debt And Capital Lease Obligation
77.99
Current Debt
57.29
Other Current Borrowings
48.23
Current Capital Lease Obligation
20.70
Current Deferred Liabilities
—
Current Deferred Revenue
—
Other Current Liabilities
121.06
Total Non Current Liabilities Net Minority Interest
1,998.55
Long Term Debt And Capital Lease Obligation
1,014.85
Long Term Debt
961.91
Long Term Capital Lease Obligation
52.94
Long Term Provisions
3.56
Non Current Pension And Other Postretirement Benefit Plans
18.17
Non Current Deferred Liabilities
82.19
Non Current Deferred Revenue
28.98
Non Current Deferred Taxes Liabilities
53.21
Other Non Current Liabilities
879.77
Stockholders Equity
4,361.19
Common Stock Equity
4,361.19
Capital Stock
0.14
Common Stock
0.14
Share Issued
1,540.98
Ordinary Shares Number
1,441.08
Treasury Shares Number
99.90
Additional Paid In Capital
12,759.14
Retained Earnings
-8,319.90
Gains Losses Not Affecting Retained Earnings
-78.18
Other Equity Adjustments
-78.18
Total Equity Gross Minority Interest
4,361.19
Total Capitalization
5,323.11
Working Capital
4,404.76
Invested Capital
5,380.40
Total Debt
1,092.84
Capital Lease Obligations
73.64
Net Tangible Assets
4,219.61
Tangible Book Value
4,219.61
Line Of Credit
9.06
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
1,127.58
+901.80%
-140.63
+87.85%
-1,157.45
+22.66%
-1,496.62
Cash Flow From Continuing Operating Activities
1,127.58
+901.80%
-140.63
+87.85%
-1,157.45
+22.66%
-1,496.62
Net Income From Continuing Operations
286.93
+144.50%
-644.79
+26.87%
-881.71
+56.00%
-2,003.82
Depreciation Amortization Depletion
141.69
-17.51%
171.76
+95.91%
87.67
+32.28%
66.28
Depreciation
131.62
-21.16%
166.94
+107.54%
80.44
+29.11%
62.30
Amortization Cash Flow
10.07
+108.77%
4.82
-33.36%
7.24
+82.07%
3.98
Depreciation And Amortization
141.69
-17.51%
171.76
+95.91%
87.67
+32.28%
66.28
Amortization Of Intangibles
10.07
+108.77%
4.82
-33.36%
7.24
+82.07%
3.98
Other Non Cash Items
-88.48
-4189.14%
-2.06
+99.45%
-377.41
-1919.31%
-18.69
Stock Based Compensation
510.86
+15.68%
441.62
+20.13%
367.62
+21.26%
303.16
Asset Impairment Charge
75.63
+1005.97%
6.84
-9.18%
7.53
—
Deferred Tax
9.47
-63.56%
25.98
+3671.12%
0.69
-66.54%
2.06
Deferred Income Tax
9.47
-63.56%
25.98
+3671.12%
0.69
-66.54%
2.06
Operating Gains Losses
0.60
-96.53%
17.18
+97.70%
8.69
-60.48%
22.00
Gain Loss On Investment Securities
0.60
-96.53%
17.18
+97.70%
8.69
—
Unrealized Gain Loss On Investment Securities
—
24.02
+48.09%
16.22
-26.25%
22.00
Change In Working Capital
190.90
+221.46%
-157.17
+57.58%
-370.54
-379.88%
132.39
Change In Receivables
-164.95
+49.93%
-329.44
-74.95%
-188.31
-161.92%
304.11
Changes In Account Receivables
-164.95
+49.93%
-329.44
-74.95%
-188.31
-161.92%
304.11
Change In Inventory
-93.17
-1.83%
-91.50
+35.09%
-140.95
-148.63%
-56.69
Change In Payables And Accrued Expense
391.60
+68.17%
232.85
+15.50%
201.59
+388.42%
41.27
Change In Accrued Expense
311.76
+179.97%
111.35
-38.17%
180.11
+294.75%
45.63
Change In Payable
79.83
-34.29%
121.50
+465.52%
21.48
+593.66%
-4.35
Change In Account Payable
79.83
-34.29%
121.50
+465.52%
21.48
+593.66%
-4.35
Change In Other Working Capital
1.29
+104.27%
0.63
+100.25%
-255.59
-68.35%
-151.82
Change In Other Current Assets
37.16
-17.64%
45.13
+272.33%
12.12
+469.29%
-3.28
Change In Other Current Liabilities
18.97
+227.83%
-14.84
-2627.77%
0.59
+148.55%
-1.21
Investing Cash Flow
-276.15
+49.64%
-548.35
-1013.86%
60.00
-94.43%
1,077.12
Cash Flow From Continuing Investing Activities
-276.15
+49.64%
-548.35
-1013.86%
60.00
-94.43%
1,077.12
Net PPE Purchase And Sale
-185.84
+62.28%
-492.66
+12.32%
-561.90
-72.66%
-325.43
Purchase Of PPE
-185.84
+62.28%
-492.66
+12.32%
-561.90
-72.66%
-325.43
Capital Expenditure
-266.53
+49.63%
-529.14
+11.26%
-596.26
-27.11%
-469.10
Net Investment Purchase And Sale
-8.39
+48.70%
-16.35
-102.48%
658.34
-57.46%
1,547.71
Purchase Of Investment
-11.83
+37.74%
-19.01
-27.56%
-14.90
+6.35%
-15.91
Sale Of Investment
3.45
+29.79%
2.65
-99.61%
673.24
-56.94%
1,563.62
Net Intangibles Purchase And Sale
-80.69
-121.23%
-36.47
-6.14%
-34.37
+76.08%
-143.66
Purchase Of Intangibles
-80.69
-121.23%
-36.47
-6.14%
-34.37
+76.08%
-143.66
Net Other Investing Changes
-1.24
+56.78%
-2.86
-37.93%
-2.08
-39.73%
-1.49
Financing Cash Flow
1,059.45
+447.66%
193.45
-53.55%
416.48
+2295.34%
-18.97
Cash Flow From Continuing Financing Activities
1,059.45
+447.66%
193.45
-53.55%
416.48
+2295.34%
-18.97
Net Issuance Payments Of Debt
3.80
-97.38%
145.08
-59.79%
360.77
+647.15%
-65.94
Issuance Of Debt
1,084.26
+23.59%
877.32
+28.26%
684.03
+94.80%
351.15
Repayment Of Debt
-1,080.46
-47.55%
-732.25
-126.52%
-323.27
+22.49%
-417.08
Long Term Debt Issuance
850.59
+9295.63%
9.05
-59.77%
22.50
-39.79%
37.37
Long Term Debt Payments
-35.68
-27.29%
-28.03
-104.76%
-13.69
0.00
Net Long Term Debt Issuance
814.91
+4393.95%
-18.98
-315.37%
8.81
-76.42%
37.37
Short Term Debt Issuance
233.68
-73.09%
868.27
+31.25%
661.53
+110.83%
313.77
Short Term Debt Payments
-1,044.78
-48.36%
-704.22
-127.48%
-309.58
+25.78%
-417.08
Net Short Term Debt Issuance
-811.11
-594.41%
164.05
-53.39%
351.95
+440.69%
-103.31
Net Common Stock Issuance
—
—
0.00
0.00
Proceeds From Stock Option Exercised
196.28
+332.59%
45.37
-18.56%
55.71
+18.63%
46.96
Net Other Financing Charges
859.37
+28545.63%
3.00
—
—
Changes In Cash
1,910.88
+485.62%
-495.53
+27.23%
-680.97
-55.31%
-438.47
Effect Of Exchange Rate Changes
60.02
+216.09%
-51.70
-539.76%
-8.08
+88.35%
-69.38
Beginning Cash Position
2,638.75
-17.18%
3,185.98
-17.78%
3,875.04
-11.59%
4,382.89
End Cash Position
4,609.65
+74.69%
2,638.75
-17.18%
3,185.98
-17.78%
3,875.04
Free Cash Flow
861.05
+228.56%
-669.77
+61.81%
-1,753.71
+10.79%
-1,965.72
Interest Paid Supplemental Data
52.45
+2.50%
51.17
+159.07%
19.75
-21.52%
25.17
Income Tax Paid Supplemental Data
—
69.43
+23.98%
56.00
+89.84%
29.50
Common Stock Issuance
—
—
0.00
0.00
Earnings Losses From Equity Investments
—
—
—
22.00
Issuance Of Capital Stock
—
—
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category